Sirolimus Patent Expiration
Sirolimus is used for treating locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors (PECOMA) in adults. It was first introduced by Pf Prism Cv
Sirolimus Patents
Given below is the list of patents protecting Sirolimus, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fyarro | US11497737 | Pharmaceutical compositions of albumin and rapamycin | Oct 28, 2040 | Aadi |
| Fyarro | US10973806 | Methods of treating epithelioid cell tumors comprising administering a composition comprising nanoparticles comprising an mTOR inhibitor and an albumin | Jun 29, 2036 | Aadi |
| Fyarro | US12133844 | Methods of treating epithelioid cell tumors | Jun 29, 2036 | Aadi |
| Fyarro | US10705070 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Mar 05, 2036 | Aadi |
| Fyarro | US12061183 | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug | Mar 05, 2036 | Aadi |
| Fyarro | US10206887 | Prion free nanoparticle compositions and methods of making thereof | Apr 15, 2030 | Aadi |
| Fyarro | US8911786 | Nanoparticle comprising rapamycin and albumin as anticancer agent | Feb 14, 2029 | Aadi |
| Rapamune |
US5989591 (Pediatric) | Rapamycin formulations for oral administration |
Sep 11, 2018
(Expired) | Pf Prism Cv |
| Rapamune | US5989591 | Rapamycin formulations for oral administration |
Mar 11, 2018
(Expired) | Pf Prism Cv |
| Rapamune |
US5536729 (Pediatric) | Rapamycin formulations for oral administration |
Mar 30, 2014
(Expired) | Pf Prism Cv |
| Rapamune |
US5100899 (Pediatric) | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jan 07, 2014
(Expired) | Pf Prism Cv |
| Rapamune | US5536729 | Rapamycin formulations for oral administration |
Sep 30, 2013
(Expired) | Pf Prism Cv |
| Rapamune | US5100899 | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
Jul 07, 2013
(Expired) | Pf Prism Cv |
| Rapamune |
US5403833 (Pediatric) | Methods of inhibiting transplant rejecton in mammals using rapamycin and derivatives and prodrugs thereof |
Oct 04, 2012
(Expired) | Pf Prism Cv |
About Veterinary Sirolimus
Sirolimus is used in a drug marketed by 1 company: Triviumvet.
Other drugs containing Sirolimus are: Felycin ca1 .
Sirolimus's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Sirolimus:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
